Business Description
Prelude Therapeutics is a clinical-stage company founded in 2016 and headquartered in Wilmington, Delaware, focused on developing cancer treatments for patients with limited options. The company is advancing a pipeline of targeted therapies aimed at specific genetic drivers of blood cancers and solid tumors, including conditions such as myelofibrosis, polycythemia vera, and advanced breast cancer. Prelude works with AbCellera Biologics to develop a novel class of antibody-based treatments designed to break down harmful proteins in cancer cells.
